Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117378

Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts.

K Harada, W Grossman, M Friedman, E R Edelman, P V Prasad, C S Keighley, W J Manning, F W Sellke, and M Simons

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Harada, K. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Grossman, W. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Friedman, M. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Edelman, E. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Prasad, P. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Keighley, C. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Manning, W. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Sellke, F. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Boston, Massachusetts.

Find articles by Simons, M. in: PubMed | Google Scholar

Published August 1, 1994 - More info

Published in Volume 94, Issue 2 on August 1, 1994
J Clin Invest. 1994;94(2):623–630. https://doi.org/10.1172/JCI117378.
© 1994 The American Society for Clinical Investigation
Published August 1, 1994 - Version history
View PDF
Abstract

The effect of basic fibroblast growth factor (bFGF) administration on regional myocardial function and blood flow in chronically ischemic hearts was studied in 26 pigs instrumented with proximal circumflex coronary artery (LCX) ameroid constrictors. In 13 animals bFGF was administered extraluminally to the proximal left anterior descending (LAD) and LCX arteries with heparin-alginate beads and 13 other animal served as controls. bFGF-treated pigs showed a fourfold reduction in left ventricular infarct size compared to untreated controls (infarct size: 1.2 +/- 0.4% vs. 5.1 +/- 1.3% of LV mass, mean +/- SEM, P < 0.05). Percent fractional shortening (% FS) in the LCX area at rest was reduced compared with the LAD region in both bFGF and control pigs. However, there was better recovery in the LCX area after rapid pacing in bFGF-treated pigs (% FSLCX/% FSLAD, 22.9 +/- 7.3%-->30.5 +/- 8.5%, P < 0.05 vs. prepacing) than in controls (16.0 +/- 7.8%-->14.3 +/- 7.0%, P = NS). Furthermore, LV end-diastolic pressure rise with rapid pacing was less in bFGF-treated than control pigs (pre-pacing; pacing; post-pacing, 10 +/- 1; 17 +/- 3; 11 +/- 1* mmHg vs 10 +/- 1; 24 +/- 4; 15 +/- 1 mmHg, *P < 0.05 vs. control). Coronary blood flow in the LCX territory (normalized for LAD flow) was also better during pacing in bFGF-treated pigs than in controls. Thus, periadventitial administration of bFGF in a gradual coronary occlusion model in pigs results in improvement of coronary flow and reduction in infarct size in the compromised territory as well as in prevention of pacing-induced hemodynamic deterioration.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 623
page 623
icon of scanned page 624
page 624
icon of scanned page 625
page 625
icon of scanned page 626
page 626
icon of scanned page 627
page 627
icon of scanned page 628
page 628
icon of scanned page 629
page 629
icon of scanned page 630
page 630
Version history
  • Version 1 (August 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts